INTRODUCTION {#s1}
============

Histone modifications, such as methylation and acetylation, play critical roles in chromatin function, transcriptional regulation, genomic stability, and DNA repair \[[@R1], [@R2]\]. These epigenetic modifications are mediated by sets of enzymatic complexes that have complementary but opposing functions, namely the "writers," which catalyze methylation and acetylation in a site-specific manner, and the "erasers," which remove the modification marks \[[@R1], [@R2]\]. Such modification marks are interpreted by "reader" proteins that recognize and are recruited to the modified histone \[[@R3], [@R4]\]. One of the largest families of epigenetic effectors capable of "reading" post-translationally modified or unmodified histone tails consists of plant homeodomain (PHD) fingers. They recruit various nuclear complexes to chromatin and stabilize them \[[@R3], [@R5]\]. Among PHD finger-containing proteins (PHFs), the PHD finger exists singly or in multiple copies, in the absence of or in conjunction with other functional modules, such as distinct histone "reading" domains, e.g., bromo-, chromo-, and Tudor domains, or a catalytic histone-associating module, such as ATPase, SET (Suppressor of variegation, Enhancer of zeste, Trithorax), and Jumonji C domains \[[@R4], [@R5]\]. PHFs can be broadly divided into the following three subgroups based on their additional functional domains and biological roles: "Epigenetic Writers," including histone methyltransferases and acetyltransferases; "Epigenetic Erasers," including histone demethylases; and "Epigenetic Readers." Thus, PHFs are vital players in regulating and maintaining the physiological functioning of epigenetic modifications in a highly context-dependent manner. Consequently, when PHFs malfunction, they are implicated in a broad range of human diseases, including cancer.

Breast cancer is the most common malignant disease in women, with more than 240,000 new cases diagnosed and 40,000 deaths in the United States per year. This heterogeneous disease is categorized into five molecular subtypes: Luminal A, Luminal B, epidermal growth factor receptor 2--enriched (HER2+), basal-like, and normal-like breast cancers \[[@R6], [@R7]\]. The majority of breast cancers (\~70%) belong to the Luminal (A and B) subtypes, characterized by expression of the estrogen receptor-α (ERα). ERα is the principal biomarker for directed hormone therapies and is the primary therapeutic target in breast cancer \[[@R8]\]. Luminal B breast cancers have lower expression of ERα and higher histologic grade, and they are less responsive to hormone therapy and have poorer outcomes than Luminal A \[[@R9]\]. Furthermore, basal-like breast cancer usually occurs in young women and is a highly aggressive subtype associated with very poor prognosis \[[@R10]\]. By deeply understanding the genetic and epigenetic alterations that are associated with the different types of breast cancer, we can identify new druggable subtype-specific targets for effective therapies.

Recent studies revealed that tumors, including breast cancer, have frequent genetic alterations in histone modifiers, including PHFs \[[@R18]--[@R20]\]. PHD fingers have been shown to play a critical role in oncogenic drivers; for example, a chromosomal translocation in the PHD finger of PHF23 or lysine (K)-specific demethylase 5A (KDM5A) was implicated in acute myeloid leukemia \[[@R11], [@R12]\]. We demonstrated that KDM4C and KDM5A are frequently amplified and overexpressed in breast cancer, particularly in aggressive basal-like subtypes \[[@R13], [@R14]\]. The PHD fingers in histone lysine methyltransferase WHSC1 (Wolf-Hirschhorn syndrome candidate 1) are critical for recruiting WHSC1 to oncogenic gene loci and driving multiple myeloma \[[@R15]\]. WHSC1L1, a homolog of WHSC1, is significantly amplified and overexpressed in a subset of breast, lung, and pancreatic cancers \[[@R16], [@R17]\]. Furthermore, the bromodomain PHD finger transcription factor (BPTF) is amplified and overexpressed in melanomas, and BPTF is required for c-MYC transcriptional activity and *in vivo* tumorigenesis \[[@R18]\]. In contrast, a *chromodomain helicase DNA binding 5* (*CHD5*) gene, which encodes an ATPase-dependent DNA-binding protein with two PHDs, is a tumor suppressor in neuroblastomas. PHD-mediated histone 3 binding is required for CHD5-mediated tumor suppression \[[@R19], [@R20]\]. In addition, the *additional sex combs like 1* (*ASXL1*) is one of the most frequently mutated genes in malignant myeloid diseases, and *ASXL1* mutations are strongly associated with a poor prognosis in these myeloid disorders \[[@R21], [@R22]\].

The initiation and progression of hematological malignancies and solid tumors have been associated with dysregulation of several PHFs. However, little is known about the rest of the genomic landscape and the clinical significance of PHFs in breast cancer. Thus, we performed a comprehensive, integrated genomic and transcriptomic analysis of 98 PHF genes in breast cancer and identified associations among recurrent copy number alteration, gene expression, clinicopathological features, and survival of patients. This approach enabled us to identify a subset of PHF genes that were recurrently altered with high prevalence, such as *PYGO2* (*pygopus family PHD finger 2*), *ZMYND8* (*zinc finger and MYND \[myeloid, Nervy, and DEAF-1\] domain containing 8*), *ASXL1*, and *CHD3* (*chromodomain helicase DNA binding protein 3*). High expression of ZMYND8 was significantly correlated with patient survival and was likely involved in a positive feedback circuit of the ER pathway in breast cancer. Furthermore, we found that JQ-1, a bromodomain and extra terminal (BET) inhibitor, suppressed ZMYND8 expression in breast cancer. These findings prioritize a subset of PHFs for future research focused on understanding molecular mechanisms and therapeutic potentials in breast cancer.

RESULTS {#s2}
=======

Copy number and expression profiling of PHFs in breast cancer {#s2_1}
-------------------------------------------------------------

Genetic alterations, including copy number alteration (CNA) and somatic mutation, are a universal hallmark of cancer \[[@R23], [@R24]\]. We hypothesized that PHFs with recurrent genetic alterations might play important roles in different types of breast cancer and hence serve as novel therapeutic targets. Based on the current ChromoHub database, there are 99 PHFs in the human genome ([Supplementary Figure S1 and Table S1](#SD1){ref-type="supplementary-material"}) \[[@R25]\]. We first analyzed CNAs and mutations in 98 PHF genes (excluding *KDM5D* on chromosome Yq11) compiled from 960 breast cancer specimens in The Cancer Genome Atlas (TCGA) *via* cBioPortal \[[@R26], [@R27]\]. The copy number for each PHF was generated by the copy number analysis algorithm GISTIC (Genomic Identification of Significant Targets in Cancer) and categorized, as copy number level per gene, into the following: high-level amplification, low-level gain, diploid, heterozygous deletion, and homozygous deletion \[[@R26], [@R27]\]. We first grouped the copy number of each PHF gene of TCGA breast cancer samples into amp/gain (high-level amplification and low-level gain), diploid, and deletion (heterozygous or homozygous deletions). As shown in Table [1](#T1){ref-type="table"} and [Supplementary Table S2](#SD1){ref-type="supplementary-material"}, the 11 most frequently (\>40%) amplified/gained PHF genes were *KDM5B*, *ASH1L*, *PYGO2*, *PHF20L1*, *CREBBP*, *FBXL19*, *DIDO1*, *ZMYND8*, *PHF20*, *ASXL1*, and *BPTF*; and the 9 most frequently (\>40%) deleted genes were *PHF23*, *CHD3*, *RAI1*, *KMT2A*, *TCF20*, *PHF21B*, *PHF11*, *EP300*, and *BRD1*. The most frequently (\>1.5%) mutated PHF genes were *KMT2C*, *KMT2D*, *CHD4*, *ASH1L*, *ASXL3*, *ASXL2*, *KMT2A*, and *BAZ2B*. Notably, *ASH1L* exhibited a higher frequency of both amp/gain (73.93%) and mutation (1.77%), whereas *CHD3* and *KMT2A* showed higher frequency of both genetic deletion (61% and 49.01%, respectively) and mutation (1.46% and 1.67%, respectively) in breast cancer (Table [1](#T1){ref-type="table"} and [Supplementary Figure S2](#SD1){ref-type="supplementary-material"}).

###### Frequency (%) of genetic and transcriptional alterations of PHFs that are highly prevalent in TCGA breast cancers

  Gene      Location           DNA Alterations   mRNA Expression Levels                                  
  --------- ------------------ ----------------- ------------------------ ------- ------ ------- ------- -------
  PYGO2     1q21.3             73.62             25.03                    1.36    0.10   51.41   41.92   6.67
  KDM5B     1q32.1             75.81             22.63                    1.56    1.25   46.09   48.80   5.11
  PHF20L1   8q24.22            59.65             35.56                    4.80    0.73   41.40   52.03   6.57
  ASH1L     1q22               73.93             24.50                    1.56    1.77   37.96   51.51   10.53
  CREBBP    16p13.3            53.49             38.16                    8.34    1.46   32.64   55.16   12.20
  BPTF      17q24.2            41.50             46.40                    12.10   1.36   32.01   53.81   14.18
  DIDO1     20q13.33           48.38             47.13                    4.48    0.94   31.60   55.16   13.24
  PHF20     20q11.22-q11.23    44.11             50.89                    5.01    0.31   27.53   59.12   13.35
  ZMYND8    20q13.12           46.72             48.80                    4.48    0.52   19.60   69.45   10.95
  FBXL19    16p11.2            52.03             39.62                    8.34    0.21   19.29   70.91   9.80
  ASXL1     20q11.21           42.44             52.87                    4.69    0.52   27.53   58.29   14.18
  ASXL2     2p23.3             14.91             67.15                    17.94   1.67   17.62   64.03   18.35
  ASXL3     18q12.1            15.33             55.89                    28.78   1.67   2.19    97.81   0.00
  CHD3      17p13.1            5.53              33.47                    61.00   1.46   6.26    58.60   35.14
  CHD4      12p13.31           25.23             60.38                    14.39   2.09   19.29   64.65   16.06
  CHD5      1p36.31            7.30              53.28                    39.42   1.46   1.67    98.33   0.00
  KMT2A     11q23.3            9.38              41.61                    49.01   1.67   10.74   63.82   25.44
  KMT2C     7q36.1             24.71             55.47                    19.81   6.99   15.95   68.72   15.33
  KMT2D     12q13.12           20.13             65.69                    14.18   2.40   17.62   64.23   18.14
  BAZ2B     2q24.2             8.45              69.86                    21.69   1.56   12.41   69.03   18.56
  BRD1      22q13.33           12.20             42.54                    45.26   0.63   11.05   55.89   33.06
  EP300     22q13.2            10.32             44.00                    45.67   1.15   12.20   64.13   23.67
  PHF11     13q14.2            7.61              46.30                    46.09   0.31   9.38    61.21   29.41
  PHF21B    22q13.31           11.37             42.34                    46.30   0.31   3.86    96.14   0.00
  TCF20     22q13.3; 22q13.2   10.84             42.75                    46.40   1.46   12.10   62.46   25.44
  RAI1      17p11.2            7.92              37.02                    55.06   0.42   9.28    59.54   31.18
  PHF23     17p13.1            5.11              33.37                    61.52   0.21   6.67    49.84   43.48

We next examined the mRNA expression levels of each PHF in TCGA breast cancer samples. As shown in Table [1](#T1){ref-type="table"} and [Supplementary Table S2](#SD1){ref-type="supplementary-material"}, we found that three PHFs (*PYGO2*, *KDM5B*, and *PHF20L1*) were overexpressed at the mRNA level (Z-score \> 1) in more than 40% of breast cancers. *PYGO2* had the highest frequency (51.41%) of mRNA overexpression. In contrast, the most deleted gene, *PHF23*, had the highest frequency (43.48%) of mRNA underexpression (Z-score \< -1), and *CHD3* was underexpressed in 35.14% of TCGA breast cancer samples. We also analyzed the correlation between copy number and mRNA level of 97 PHFs (excluding those of *KDM5D* and *KMT2B*, as their RNA-sequencing data were not available) from TCGA breast cancer specimens. As shown in [Supplementary Table S3](#SD1){ref-type="supplementary-material"}, almost all PHF genes had positive correlations between DNA copy number and mRNA expression, and 24 of them had a Spearman correlation coefficient (r) \> 0.5.

To determine whether the genetic alteration or mRNA expression of each PHF is specific to a breast cancer subtype, we analyzed CNA and mRNA expression independently across different subtypes of 808 breast cancer samples for which PAM50 (Prediction Analysis for Microarray 50) subtype data were available \[[@R26]\]. The frequencies of high-level amplification, low-level gain, diploid, heterozygous deletions, homozygous deletions, and somatic mutation of PHF genes in five breast cancer subtypes are shown in [Supplementary Table S4](#SD1){ref-type="supplementary-material"}. mRNA expression status of the PHF genes is shown in [Supplementary Table S5](#SD1){ref-type="supplementary-material"}. Among the 11 most amplified/gained PHF genes, 7 (*PYGO2, KDM5B*, *PHF20L1*, *ASH1L*, *PHF20*, *DIDO1*, and *ASXL1*) likely had a higher frequency of gain/amplification in both Luminal and basal subtypes of breast cancer, and 4 of them (*ZMYND8*, *BPTF*, *CREBBP*, and *FBXL19*) were more commonly amplified/gained in Luminal, particularly Luminal B breast cancer, than in the normal-like subtype (Figure [1A](#F1){ref-type="fig"}, [Supplementary Table S4](#SD1){ref-type="supplementary-material"}). Among the 9 most deleted PHF genes, *PHF23*, *CHD3*, *RAI1*, and *PHF11* had more deletions in Luminal, HER2+, or basal-like subtypes, while *KMT2A*, *TCF20*, *PHF21B*, *EP300*, and *BRD1* had more deletions in the Luminal B subtype (Figure [1B](#F1){ref-type="fig"}, [Supplementary Table S4](#SD1){ref-type="supplementary-material"}). A detailed analysis of expression levels of each PHF in the five breast cancer subtypes also revealed that expression levels of *PYGO2* and *KDM5B* were higher in Luminal, HER2+, and basal-like, compared with their expression levels in the normal-like subtype of breast cancer (Figure [1](#F1){ref-type="fig"}, [Supplementary Figure S3](#SD1){ref-type="supplementary-material"}, and [Supplementary Table S5](#SD1){ref-type="supplementary-material"}). We also found that *ZMYND8* has a higher expression level in Luminal and HER2+, but not in the basal-like subtype, compared with that in the normal-like subtype breast cancer (Figure [1](#F1){ref-type="fig"}). In contrast, the commonly deleted genes *CHD3* and *KMT2A* showed underexpression in HER2+ and basal-like subtypes (Figure [1](#F1){ref-type="fig"}, [Supplementary Table S5](#SD1){ref-type="supplementary-material"}).

![Frequencies of *PYGO2* and *ZMYND8* copy number increase **A**., and *CHD3* and *KMT2A* deletion **B**. across five subtypes of TCGA breast cancer samples. **C**. Expression levels of *PYGO2*, *ZMYND8*, *CHD3*, and *KMT2A* across five subtypes of TCGA breast cancer samples. The differences in *PYGO2*, *ZMYND8*, *CHD3*, and *KMT2A* mRNA levels among breast cancer subtypes are statistically significant (*p* \< 0.05).](oncotarget-08-13099-g001){#F1}

To validate our findings from TCGA breast cancer dataset regarding PHF genetic alterations, we conducted an independent analysis using the METABRIC dataset, which contains approximately 2000 primary breast cancers with long-term clinical follow-up data. We found that 17 PHF genes, including *PYGO2*, *KDM5B*, *PHF20L1*, and *ZMYND8*, had a higher frequency (\>10%) of gain/amplification, and 9 PHF genes, including *CHD3* and *PHF23*, had a higher frequency of deletion in the METABRIC breast cancer samples ([Supplementary Table S6](#SD1){ref-type="supplementary-material"}), although the frequency of gain/amplification identified in the METABRIC dataset is lower than that of TCGA dataset, possibly due to the different CNA analysis platforms and calling algorithms. Furthermore, statistical analyses of copy number alterations in METABRIC dataset define 32 regions of amplification and 13 regions of deletion \[[@R28]\]. We analyzed these 45 genomic regions and found that 11 PHF genes are localized in significantly amplified regions, including *KDM5A* in 1q32, *WHSC1L1* and *ASH2L* in 8p11-12, *PHF20L1* in 8q13-24, and *ZMYND8* in 20q13 ([Supplementary Table S7](#SD1){ref-type="supplementary-material"}). We also found that Luminal B breast cancer had the highest frequency of *ZMYND8* gain/amplification in the METABRIC dataset ([Supplementary Figure S4A](#SD1){ref-type="supplementary-material"}). Expression levels of PYGO2, KDM5B, PHF20L1, and ZMYND8 were also significantly higher in tumor samples compared to that in non-tumor breast tissue ([Supplementary Table S8](#SD1){ref-type="supplementary-material"}). Again, mRNA expression levels of *PYGO2* and *KDM5B* were higher in Luminal, HER2+, and basal-like breast cancers, and *ZMYND8* was higher in Luminal B and HER2+ subtypes compared with that in the normal-like subtype in the METABRIC dataset ([Supplementary Figure S4B](#SD1){ref-type="supplementary-material"}; *p* \< 0.001).

Recurrent mutations of CHD3-5 and ASXL1-3 genes in breast cancer {#s2_2}
----------------------------------------------------------------

Among mutated PHF genes in TCGA breast cancer samples, we found that 33 PHF genes contained mutations in the PHD domains ([Supplementary Table S9](#SD1){ref-type="supplementary-material"}). We noticed that three PHF subfamilies (*KMT2A/C/D*, *ASXL1-3*, and *CHD3-5*) had higher frequencies of mutation. We also analyzed frequencies of mutation number per gene size, and found that the higher frequent mutation ratios were associated with *KMT2C*, *CHD4*, *ASXL2*, and *BAZ2B*, which have mutations of more than 2 per kilobase (kb) ([Supplementary Table S9](#SD1){ref-type="supplementary-material"}). We previously reported a mutation spectrum for *KMT2C* and *KMT2D* and proposed their function as tumor suppressors in breast cancer \[[@R29]\]. Here, we focused on analyzing the mutation spectrum of *ASXL1-3* and *CHD3-5* genes in breast cancer.

The ASXL family consists of three members (ASXL1, ASXL2 and ASXL3) that share a common domain architecture: HARE-HTH, ASXH, and a C-terminal PHD. As shown in Figure [2A](#F2){ref-type="fig"} and [Supplementary Table S10](#SD1){ref-type="supplementary-material"}, we identified a total of 40 ASXL family mutations, consisting of 7 mutations of *ASXL1*, 17 mutations of *ASXL2*, and 16 mutations of *ASXL3*. One tumor sample (TCGA-BH-A0B9) had three missense mutations (D893H, E1006K, and G1198V) in the *ASXL1* gene, and one sample (TCGA-AN-A046) had two nonsense mutations (R357\* and R312\*) in the *ASXL2* gene. Most of the mutations in the *ASXL* genes are localized to the amino-terminal end of the PHD domain. Previous studies demonstrated that truncation mutations of *ASXLs* occur in autism, Bohring--Opitz and related syndromes, hematological malignancies, and several solid tumors \[[@R21], [@R22], [@R30]\]. Therefore, we predict that mutations at the amino terminus of the PHD might result in the gain or loss of function of ASXL proteins in breast cancer.

![Mutational spectra of ASXL1-3 and CHD3-5 genes in breast cancer\
The images show protein domains and the positions of somatic mutations in ASXL1-3 **A**. and CHD3-5 **B**. in TCGA breast cancers. A red dot indicates a nonsense mutation, frameshift deletion, insertion, or splice; a green dot indicates a missense mutation; and a black dot indicates an inframe insertion or deletion. The data were obtained from TCGA database via cBioPortal.](oncotarget-08-13099-g002){#F2}

CHD3, CHD4, and CHD5 belong to the second subfamily of CHD proteins, which are characterized by an SNF2-like domain located in the central region as well as tandem PHD and chromodomains at their C-termini \[[@R31], [@R32]\]. The SNF2-like domain is responsible for ATP-dependent chromatin remodeling. As shown in Figure [2B](#F2){ref-type="fig"} and [Supplementary Table S11](#SD1){ref-type="supplementary-material"}, we identified a total of 51 CHD3-5 family mutations, consisting of 14 mutations of *CHD3*, 22 mutations of *CHD4*, and 15 mutations of *CHD5*, most of which were missense mutations. In the *CHD4* gene, tumor sample TCGA-C8-A27B had two missense mutations (P90Q and A235P), and TCGA-D8-A1JN had one missense mutation (I989F) and an X34 splice. In the *CHD5* gene, one sample (TCGA-D8-A1JK) had a missense mutation (H1820Y) and frameshift deletion (G976Afs\*11). Furthermore, we found that one sample (TCGA-BH-A1FC) had a mutation (D407H) in the region of the first PHD-finger of CHD3 (Figure [2B](#F2){ref-type="fig"}).

Association of PHF gene expression with clinical features and survival of breast cancer patients {#s2_3}
------------------------------------------------------------------------------------------------

To investigate the clinical relevance of PHF alterations in breast cancer, we examined expression levels of each PHF gene at different stages of TCGA breast cancer samples. The means of Z-score and *p*-value for each PHF gene across four American Joint Committee on Cancer (AJCC) stages of breast cancer are shown in [Supplementary Table S12](#SD1){ref-type="supplementary-material"}. Among 11 most commonly amplified/overexpressed PHF genes, we found that three genes, *ZMYND8, PHF20*, and *DIDO1*, were significantly highly expressed in advanced-stage breast cancers (T-test: Stage I+II vs III+IV; *p* \< 0.05; Figure [3A](#F3){ref-type="fig"} and [Supplementary Table S12](#SD1){ref-type="supplementary-material"}). Because several PHFs were more commonly amplified/gained in the Luminal subtype of breast cancer, we then examined the expression levels of each PHF gene in different stages of only Luminal breast cancer samples. We found that *ZMYND8* and *PHF20*, but not *DIDO1*, also had significantly higher expression in advanced stages of Luminal breast cancers (*p \<* 0.05; [Supplementary Table S13](#SD1){ref-type="supplementary-material"}).

![**A**. Expression levels of *ZMYND8* across different AJCC stages of TCGA breast cancer samples. **B**. Kaplan-Meier plots of overall survival associated with mRNA expression levels of *ZMYND8* in TCGA breast cancers. **C**. Multivariate analysis revealed that *ZMYND8* expression was independent of prognostic variables influencing overall survival of TCGA breast cancer patients.](oncotarget-08-13099-g003){#F3}

Next, to analyze the relationship between PHF mRNA expression and overall survival of breast cancer patients, samples were divided into high (Z-score \> 0) and low (Z-score =\< 0) groups based on the mRNA expression level of each PHF. [Supplementary Table S14](#SD1){ref-type="supplementary-material"} summarizes the results of a log-rank statistical analysis of 97 PHFs in breast cancer. High mRNA levels of *ZMYND8*, *BPTF*, *PHF20*, *WHSC1L1*, and *PHF20L1* were positively associated with shorter survival in breast cancer patients (*p* \< 0.05) (Figure [3B](#F3){ref-type="fig"}, [Supplementary Table S14](#SD1){ref-type="supplementary-material"}). We also performed survival analyses of each PHF gene in Luminal (A and B) subtypes only. In the Luminal subtype, we found that high mRNA levels of six PHF genes, *PHF20*, *PYGO1*, *KDM5A*, *PHF6*, *BPTF*, and *CHD5*, were significantly associated (*p* \< 0.05) with shorter survival in breast cancer patients. Conversely, low mRNA levels of *KDM4B* and *ING* were significantly associated (*p* \< 0.05) with shorter survival ([Supplementary Table S15](#SD1){ref-type="supplementary-material"}). We then performed a multivariate analysis to investigate whether the expression level of each PHF was predictive of poor prognosis compared with standard prognostic markers, including age at diagnosis, ER status, progesterone receptor status, HER2 status, tumor size, lymph node status, metastasis status, and molecular subtype (basal vs. non-basal). In addition to *PHF20L1*, which we previously reported, we also found that high mRNA level of *ZMYND8* (*p* = 0.034, hazard ratio \[HR\] = 1.92) was independently associated with shorter survival of TCGA breast cancer patients (Figure [3C](#F3){ref-type="fig"}) \[[@R33]\]. Validating this analysis using the METABRIC dataset, we found that *ZMYND8* was similarly highly expressed in breast cancer samples of advanced stage and higher grade ([Supplementary Figure S5](#SD1){ref-type="supplementary-material"}). We confirmed that higher expression of *ZMYND8* was correlated with a poor prognosis (*p* = 0.034, HR = 1.16) in METABRIC breast cancer samples.

ZMYND8 in the feedback circuit of the ER pathway was suppressed by the BET inhibitor {#s2_4}
------------------------------------------------------------------------------------

In our analysis of the genetic alterations of PHFs in breast cancer, we found that ZMYND8 had a higher frequency of amplification and overexpression in Luminal B breast cancer, and its overexpression was associated with shorter survival in patients in both TCGA and METABRIC datasets. We further examined ZMYND8 expression in a panel of breast cancer cells. Quantitative reverse transcription PCR (qRT-PCR) and RNA sequencing showed that ZMYND8 was expressed more in ER-positive Luminal than ER-negative basal cell lines (Figure [4A](#F4){ref-type="fig"} and [Supplementary Figure S6](#SD1){ref-type="supplementary-material"}). Because a previous study demonstrated that ZMYND8 physically binds ERα in breast cancer \[[@R34]\], and because we found that mRNA levels of ZMYND8 were positively correlated with expression levels of the *ESR1* (estrogen receptor 1) gene (Spearman correlation coefficient (r) of 0.34 in TCGA breast cancer samples), we tested whether ZMYND8 is a downstream target of the ER pathway. We treated two ER-positive Luminal breast cancer cell lines, T47D and ZR75-1, with tamoxifen, the most widely used nonsteroidal selective ER modulator for adjuvant therapy of ER-positive breast cancer. [Supplementary Figure S7](#SD1){ref-type="supplementary-material"} shows that expressions of ERα target genes *TFF1* (*trefoil factor 1*) and *MYB* were suppressed in T47D cells after tamoxifen treatment. We found that expression of ZMYND8 at mRNA and protein levels was also significantly reduced in those two cell lines after tamoxifen treatment (Figure [4B](#F4){ref-type="fig"} and [4C](#F4){ref-type="fig"}). Next, we analyzed published data of ERα chromatin immunoprecipitation sequencing (ChIP-Seq) in ER-positive breast cancer cell lines \[[@R35], [@R36]\]. We found that ERα directly bound to the genomic regions of the *ZMYND8* gene. [Supplementary Figure S8](#SD1){ref-type="supplementary-material"} illustrates ChIP-Seq binding sites of ERα at the *ZMYND8* genomic loci in T47D cells \[[@R36], [@R37]\]. Thus, these data suggest that a positive regulatory loop between ERα and ZMYND8 exists in ER-positive luminal breast cancer.

![**A**. mRNA expression levels of *ZMYND8*, measured by qRT-PCR, in a panel of 21 breast cancer cell lines. mRNA expression levels in the immortalized but nontumorigenic breast epithelial cell line MCF10A cells were arbitrarily set as 1. Cell lines: green indicates MCF10A; blue, Luminal breast cancer cell lines; pink, HER2+ breast cancer cell lines; and red, basal-like breast cancer cell lines. **B**. qRT-PCR and **C**. immunoblot analysis of ZMYND8 expression after treatment with tamoxifen (TAM) in T47D and ZR75-1 cells (\**p* \< 0.05 and \*\**p* \< 0.01, Student\'s *t*-test). Protein levels of ERα were also measured by western blot after TAM treatment.](oncotarget-08-13099-g004){#F4}

Recent studies demonstrated that bromodomain-containing protein-4 (BRD4) plays an important role in promoting estrogen-regulated transcription of ER-positive breast cancer cells \[[@R38]\]. BRD4 is a member of the BET family, which also includes BRD2, BRD3, and BRDT. BRD4 is a major target of BET inhibitors, such as JQ-1, which also suppress breast cancer growth inhibition *in vitro* and *in vivo* \[[@R39]\]. We validated that JQ-1 inhibited growth and survival of both ER-positive luminal T47D and basal-like SUM159 breast cancer cells (Figure [5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}). The Western blot assays demonstrated that JQ-1 downregulated c-MYC, a known target of BRD4, but there was no measurable effect on ERα expression in T47D cells (Figure [5C](#F5){ref-type="fig"} and [Supplementary Figure S9](#SD1){ref-type="supplementary-material"}). We also found that JQ-1 dramatically suppressed the mRNA and protein expression of ZMYND8 in both ER-positive T47D and ER-negative SUM159 cells (Figure [5C](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}). Thus, ZMYND8 expression is likely regulated by multiple mechanisms, including gene amplification, ERα, and possibly BRD4 pathways in breast cancer.

![**A**. Representative images of cells stained with crystal violet show the effect of JQ-1 on growth and survival of ER-positive T47D and ER-negative SUM159 cells. **B**. Bar graphs show relative cells growth after JQ-1 treatment in T47D and SUM159 cells. **C**. Immunoblot and **D**. qRT-PCR analysis of ZMYND8 expression after treatment with JQ-1 in T47D and SUM159 cells (\**p*\<0.05 and \*\**p*\<0.01, Student\'s *t*-test). Protein levels of MYC were also measured by western blot after JQ-1 treatment in T47D and SUM159 cells.](oncotarget-08-13099-g005){#F5}

DISCUSSION {#s3}
==========

By conducting integrated genomic and transcriptomic analyses of breast cancers with different molecular subtypes and clinicopathological features, we identified a subset of PHF genes, including *PGYO2*, *CHD3*, and *ZMYND8*, that have high frequencies of CNA and altered mRNA expression. Different subtypes of breast cancer had different patterns of copy number and expression of each PHF. Several PHF genes, e.g. *PYGO2*, were amplified/overexpressed likely independent of subtype. Copy number increase and overexpression of ZMYND8 were more prevalent in Luminal B subtypes and were significantly associated with shorter survival of breast cancer patients. Interestingly, we found that ZMYND8, which physically binds ERα, is a downstream target of ERα, suggesting that ZMYND8 is in a positive feedback circuit of the ER pathway in breast cancer. Furthermore, the expression of ZMYND8 was repressed after treatment with the BET inhibitor JQ-1 in breast cancer cells.

The PHD finger, which is approximately 50-80 amino acids long, is a sequence-specific histone recognition protein domain \[[@R5]\]. The PHD finger consists of two anti-parallel β-sheets and a C-terminal α-helix, which is stabilized by two zinc atoms. Biochemically, PHD fingers are classified into canonical PHD fingers that bind to trimethylated histone H3 lysine 4 (H3K4me3) or noncanonical PHD fingers that bind to differently modified histones or DNA. H3K4me3 is a histone mark associated with active transcription. PHD binding of H3K4me3 occurs through an aromatic cage, similar to those observed in chromodomain, PWWP (Pro-Trp-Trp-Pro), and Tudor domains \[[@R4], [@R5]\]. Of note, one tryptophan (Trp) residue in the second β-strand of canonical PHD is absolutely conserved; this Trp forms one of the walls of the aromatic cage for H3K4me3 binding \[[@R5]\]. In contrast, noncanonical PHD fingers that bind unmodified histone H3 lack the second β-strand Trp. Among 99 PHF proteins with PHD fingers based on the current ChromoHub database, 57 proteins, including PYGO2, contain only one PHD, and most of them bind H3K4me3 ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}). Thirty-two PHF proteins, e.g. CHD3-5, have two PHDs, and many of them, particularly those with two PHDs in tandem, bind unmodified histone H3, due to the lack of conserved Trp residues in both PHDs. In addition, 11 PHF proteins have more than two PHDs; one of them is histone methyltransferase KMT2C, which has eight PHDs, and likely has diverse histone-binding and biological roles \[[@R40]\]. Furthermore, many PHFs also have additional epigenetic effector domains, including bromo-, chromo-, Tudor, and PWWP domains. We found the coexistence of a PHD and bromodomains in 22 PHF proteins, including BPTF and ZMYND8; thus, that pairing is considerably more frequent than the pairing of any other epigenetic effector domains. Bromodomain is a "reader" of lysine acetylation \[[@R39]\]. A combined readout of epigenetic marks by the PHD and bromodomain has been characterized in several PHFs \[[@R4], [@R41]\]. For example, the PHD finger domain of BPTF recognizes methylation signatures at H3K4me2/3, and the bromodomain selectively binds to the H4K16ac acetylation mark \[[@R41]\]. Thus, structure-function studies have highlighted the fact that PHD fingers recognize histone tails with relatively high specificity and affinity, making them critical components of various epigenetic mechanisms.

In this study, we identified four PHFs, *PYGO2*, *KDM5B*, *PHF20L1*, and *ASH1L*, which were most commonly amplified/overexpressed in breast cancer (Table [1](#T1){ref-type="table"}). These data agree with and consolidate prior reports on the genetic alterations and oncogenic potentials of these PHFs in various tumors. PYGO2 protein contains one PHD domain, which regulates β-catenin-mediated transcription through an interaction with methylated H3K4 marks \[[@R42], [@R43]\]. Recent studies demonstrated that PHD-mediated PYGO2 chromatin binding supports and enhances mammary gland progenitor proliferation \[[@R44], [@R45]\]. Furthermore, loss of epithelial Pygo2 delayed mammary tumor onset in mouse mammary tumor virus (MMTV)-Wnt1 transgenic mice \[[@R46]\]. *KDM5B* was originally discovered as a gene that was upregulated by HER2 in breast cancer cells \[[@R47]\]. Consistent with this, we found that the mRNA expression level of *KDM5B* was slightly higher in the HER2+ subtype, compared with luminal and basal-like subtypes, in both TCGA and METABRIC breast cancer samples ([Supplementary Figure S3](#SD1){ref-type="supplementary-material"}). Inhibiting KDM5B in breast cancer cells has been shown to reduce proliferation-reduced mammary tumor growth *in vitro* and *in vivo* \[[@R48], [@R49]\]. In addition, COLT analysis of the genes essential for cancer cell survival and proliferation in 29 breast cancer lines identified KDM5B as a hit in 12 (41%) of these lines ([Supplementary Table S16](#SD1){ref-type="supplementary-material"}) \[[@R50]\]. PHF20L1 protein contains two types of histone-reading modules, PHD and Tudor domains. PHF20L1 is amplified and overexpressed in a subset of basal-like and Luminal B breast cancers. We recently demonstrated that knockdown of PHF20L1 inhibits cell proliferation in breast cancer cell lines \[[@R33]\]. We speculate that PHF20L1 likely functions as a critical tethering factor, *via* its PHD and Tudor domains, to regulate DNA and histone methylation signals in breast cancer \[[@R33]\]. ASH1L, a member of the trithorax group, is the H3K36 methyltransferase. A recent study demonstrated that ASH1L is a crucial regulator of key leukemia target genes and contributes to leukemia pathogenesis \[[@R51]\]. Thus, these four PHFs are most likely proto-oncogenes in breast cancer.

In breast cancer, the two most commonly deleted/underexpressed PHF genes were *PHF23* and *CHD3*. Fusion of the *PHF23* gene with the *NUP98* (*Nucleoporin 98*) gene frequently recurs in acute myeloid leukemia \[[@R11]\]. PHF23 protein contains the canonical PHD finger at the C-terminus, and the PHD finger is retained in the *NUP98-PHF23* fusion. The leukemogenic potential of the NUP98-PHF23 fusion protein relies on the ability of the PHD finger to recognize the H3K4me3/2 marks \[[@R12]\]. CHD3, CHD4, and CHD5 proteins, which share common ATPase domains, tandem PHD domains, and chromodomains, are catalytic components of the NuRD (nucleosome remodeling histone deacetylase) complex \[[@R31]\]. CHD3 and CHD4 are expressed ubiquitously in every normal tissue, whereas CHD5 is preferentially expressed in the nervous system and testis. Both *CHD3* and *PHF23* genes are localized at 17p13.1, the TP53 region. A recent study demonstrated that deletions linked to TP53 loss drive cancer through p53-independent mechanisms \[[@R52]\]. In that study, a shRNA library targeting the \~100 protein-coding genes (excluding *TP53*) in mouse chromosome 11B3 syntenic to human 17p13.1 was screened for its tumor-suppressor activity in mouse models. Among 17 identified genes, CHD3 and PHF23 were considered potential tumor suppressors \[[@R52]\]. In the future, it will be important to determine how CHD3 and PHF23 play tumor-suppressor roles in a p53-dependent or independent manner in breast cancer.

In contrast to CHD3 and CHD5, which most likely function as tumor suppressors, the role of CHD4 in various tumors appears to be quite complex. It exhibits both oncogenic and tumor-suppressing properties \[[@R20], [@R31], [@R53]--[@R55]\]. Biochemically, the two PHD fingers of CHD4 are able to bind two distinct H3 tails with unmodified H3K4 and/or H3K9me3, but not H3K4me3 \[[@R56]\]. As the major component of NuRD, CHD4 has been implicated in regulating gene transcription and facilitating DNA repair \[[@R55], [@R56]\]. Compelling evidence indicates that CHD4 is a biomarker of drug sensitivity in cancer cells. For example, using high-throughput genomics, Geeleher *et al*. revealed that expression of CHD4 predicted the sensitivity of the histone deacetylase (HDAC) inhibitor Vorinostat in a large panel of cancer cell lines \[[@R57]\]. Furthermore, global proteomic analysis of the NCI-60 cancer cell lines revealed that the CHD4 protein is the second most recurrent and significant protein associated with the sensitivity of 97 different drugs \[[@R58]\]. Depletion of CHD4 sensitizes the CAMA1 breast cancer cell line to Vorinostat or leukemia cells to genotoxic agents and reduces tumor formation \[[@R53], [@R57]\]. In contrast to CHD3, the expression level of CHD4 was higher in Luminal, HER2+, and basal-like breast cancer compared with normal-like breast cancers ([Supplementary Figure S10](#SD1){ref-type="supplementary-material"}). Thus, CHD4 appears to play various roles in tumorigenesis and in the development of drug resistance.

In a recent study of 560 breast cancer samples with the whole-genome sequences, Nik-Zainal *et al*. identified 93 protein-coding cancers carrying probable driver mutations \[[@R59]\]. Five of them (*KMT2C*, *KMT2D*, *ASXL1*, *CREBBP*, and *PHF6*) were PHF genes. Our previous study, together with others, demonstrated that KMT2C and KMT2D function as tumor suppressors \[[@R29], [@R60]\]. The *ASXL1* is frequently mutated in a range of myeloid malignancies \[[@R21], [@R22]\]. Most cancer-associated ASXL1 mutations give rise to truncated proteins that retain the amino-terminal BAP1 (BRCA1 associated protein 1)-interacting region of ASXL1, but lose the carboxy-terminal PHD domain \[[@R21], [@R22], [@R61]\]. Accumulating data suggest that ASXL1 functions as a haploinsufficient tumor suppressor in the hematopoietic system \[[@R61]\]. In contrast, other studies suggested that *ASXL1* mutations might confer a gain-of-function, rather than loss-of-function, by generating a stable truncated protein lacking the PHD domain that either serves as a dominant negative function or generates a new function \[[@R61]\]. In this study, we also found that ASXL1 gene, localized at 20q11 region, is commonly amplified/gained in breast cancer (Table [1](#T1){ref-type="table"}). Thus, functional roles of ASXL1 might be altered by gene amplification or gain-of-function mutations in a set of breast cancer.

A finding of particular interest from our study is the dysregulation of ZMYND8 in a subset of breast cancers. The ZMYND8 protein, which contains an N-terminal PHD-bromo-PWWP (PBP) cassette and a C-terminal MYND (Myeloid-Nervy-DEAF1) domain ([Supplementary Figure S11](#SD1){ref-type="supplementary-material"}), has a wide range of interacting partners, including transcription factors, chromatin remodeling complexes, and histone demethylase/deacetylase enzymes. Analysis of the human endogenous coregulatory complexome revealed that the PBP cassette of ZMYND8 interacts directly with ERα, and both co-occupy a set of genomic sites of known ERα-binding sites \[[@R34]\]. Results of gene expression and reporter assay studies confirmed the coactivator functions of ZMYND8 for ER transcriptional activity \[[@R34]\]. A recent study revealed that ZMYND8 reads the dual histone modifications H3K4me1-H3K14ac via PHD-bromo cassette, and it is associated with repression of metastasis-linked genes \[[@R62]\]. The MYND domain of ZMYND8 is responsible for its interactions with the NuRD complex, notably the core catalytic component CHD4 \[[@R54]\]. Importantly, ZMYND8 has been identified as a new DDR (DNA Damage Response) factor; ZMYND8 recruits CHD4 to the sites of DNA damage and represses transcription and facilitates DNA repair by homologous recombination \[[@R54], [@R63]\]. Thus, ZMYND8 is implicated in both transcriptional activation and silencing, as well as DNA damage in a context-specific manner. In the present study, we provided additional evidence that ZMYND8 was involved in a positive feedback circuit involving the ER pathway in breast cancer, where the interaction between ZMYND8 and ERα promotes activation of the ERα target gene, including ZMYND itself. Furthermore, an additional regulatory mechanism, such as BRD4\'s association with super-enhancers, might regulate ZMYND expression in both ER-positive and ER-negative breast cancers. It is worth noting that, based on the NCBI database, at least 18 transcript variants of ZMYND8 exist. Western blot also revealed the additional protein bands with molecular weight lower than full-length ZMYND8 in breast cancer cell lines, particularly Luminal subtypes ([Supplementary Figure S12](#SD1){ref-type="supplementary-material"}). Furthermore, fusion of ZMYND8 has been identified in lymphoma and breast cancer; both of the ZMYND8 fusions reportedly remove the MYND domain but retain the N-terminal PBP cassette \[[@R64], [@R65]\]. ZMYND8 gene is localized at chromosomal region 20q13, which also contains candidate breast cancer oncogenes: *MYBL2* (*MYB proto-oncogene like 2*), *ZNF217* (*zinc finger protein 217*), and *AURKA* (aurora kinase A) \[[@R66]\]. As shown in [Supplementary Figure S13](#SD1){ref-type="supplementary-material"}, we found that most ZMYND8-amplified breast cancer samples also showed the amplification of other candidate oncogenes at the 20q13 region. It is necessary to further investigate whether and how ZMYND8 contribute, independently or cooperatively with other 20q13-amplified genes, to breast tumorigenesis.

In conclusion, our integrated genomic and transcriptomic analysis identified a broad spectrum of genetic alterations in PHF genes involved in different subtypes of breast cancer. Given the higher prevalence of genomic and transcriptomic alteration of several PHFs, such as PYGO2, ZMYND8, ASXL1, and CHD3, it is necessary to further characterize their structures, roles, and the molecular mechanisms of the PHD domain that are implicated in breast cancer initiation and progression. Furthermore, inhibition of critical epigenetic reader domains, such as PHD fingers, is emerging as the next frontier in epigenetic drug development. A few inhibitors that target PHD fingers, e.g., PYGO2-PHD and the third PHD of KDM5A, have been reported recently \[[@R67], [@R68]\]. We anticipate that our findings, along with similar studies on other types of tumors, will help prioritize which PHFs to study in order to better understand the molecular mechanisms and discover novel therapeutic targets in oncology.

MATERIALS AND METHODS {#s4}
=====================

Cell culture {#s4_1}
------------

The cultures for the SUM series of breast cancer cell lines and the nontransformed human mammary epithelial cell line MCF10A were described previously \[[@R69]\]. The Colo824 cell line was obtained from DSMZ (Braunschweig, Germany), SUM cell lines were obtained from Dr. Stephen P. Ethier, and all other cell lines in this study were obtained from ATCC (Manassas, VA, USA). Cell growth was assessed by using an MTT assay. For clonogenic survival assays, cells were seeded in 12-well dishes and treated with JQ-1. After 12 days for SUM159 cells or 20 days for T47D cells, colonies were fixed and stained with 0.5% crystal violet. Cells were photographed and counted with an automated mammalian cell colony counter (Oxford Optronix GELCOUNT, Oxford, United Kingdom).

The cancer genome atlas (TCGA) data for breast cancer {#s4_2}
-----------------------------------------------------

The DNA copy number, mutation, and overall survival datasets of 960 breast cancer samples used in this research were obtained from the cBio Cancer Genomics Portal \[[@R26], [@R27]\]. For each PHF, the copy number was generated from the copy number analysis algorithm GISTIC (Genomic Identification of Significant Targets in Cancer) and categorized as copy number level per gene: "-2" is a deep loss (possibly a homozygous deletion), "-1" is a heterozygous deletion, "0" is diploid, "1" indicates a low-level gain, and "2" is a high-level amplification. For mRNA expression data, the relative expression of an individual gene and the distribution of a gene\'s expression in a reference population were analyzed. The reference population was either all tumors that are diploid for the gene in question or, when available, normal adjacent tissue. The returned value indicates the number of standard deviations away from the mean of expression in the reference population (Z-score). Somatic mutation data were obtained from exome sequencing \[[@R26], [@R27]\]. Breast cancer subtype and clinicopathologic information were extracted *via* the UCSC Cancer Genomics Browser ([genome-cancer.ucsc.edu](http://genome-cancer.ucsc.edu)) and the cBio Cancer Genomics Portal \[[@R6], [@R26], [@R27]\]. Among the 960 breast cancer samples, 808 had subtype data available, including 22 normal-like, 405 Luminal A, 185 Luminal B, 66 HER2+, and 130 basal-like breast cancers \[[@R26], [@R33], [@R70]\].

The METABRIC (molecular taxonomy of breast cancer international consortium) dataset {#s4_3}
-----------------------------------------------------------------------------------

The METABRIC dataset contains approximately 2000 primary breast cancers with long-term clinical follow-up data. METABRIC normal breast expression dataset (n = 144) was used as a non-cancer, tissue control. A detailed description of the dataset is presented in the original publication \[[@R28]\]. The CNAs and normalized expression data of METABRIC were downloaded with access permissions from the European Genome-phenome Archive (<https://www.ebi.ac.uk/ega>) under accession number EGAC00000000005. In the METABRIC dataset, copy number log~2~ ratios were segmented using two analytical methods, circular binary segmentation and an adapted hidden Markov model. The median of the log~2~ ratio was computed, and gene-centric alterations were categorized as amplification, gain, heterozygous loss, and homozygous loss. The data for 98 PHFs were based on the circular binary segmentation--derived copy number profiles \[[@R28]\]. The normalized gene expression profiles were generated using the Illumina Human HT-12 platform \[[@R28]\].

Semiquantitative PCR reactions {#s4_4}
------------------------------

mRNA was prepared from human breast cancer cell lines and the MCF10A cell line by using an RNeasy Plus Mini Kit (QIAGEN). mRNA was mixed with qScript cDNA SuperMix (Quanta Biosciences, Gaithersburg, MD, USA) then converted into cDNA through a reverse-transcription (RT) reaction for real-time PCR reactions. Primer sets were ordered from Life Technologies (Carlsbad, CA, USA). A PUM1 primer set was used as a control. Semiquantitative RT-PCR was performed using the FastStart Universal SYBR Green Master (Roche Diagnostics, Indianapolis, IN, USA).

Immunoblotting and antibodies {#s4_5}
-----------------------------

Whole-cell lysates were prepared by scraping cells from dishes into cold RIPA lysis buffer. After centrifugation at high speed, protein content was estimated by the Bradford method. A total of 20--50 μg of total cell lysate was resolved by sodium dodecyl sulfate--polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane. Antibodies used in the study included anti-ZMYND8 (1:1000, Bethyl Laboratories A302-089A, Montgomery, TX, USA), anti-MYC (1:1000, Cell Signaling D3N8F, Danvers, MA, USA), anti-ERα (1:1000, Cell Signaling 8644, Danvers, MA), anti-β-actin (1:5000, Sigma-Aldrich A5441, St. Louis, MO), and anti-β-tubulin (1:5000, Sigma-Aldrich T8328, St. Louis, MO, USA).

Statistical analysis {#s4_6}
--------------------

Statistical analyses were performed using R software (<http://www.r-project.org>) and Graphpad Prism (version 6.03). Correlations between copy numbers and mRNA levels of each PHF from TCGA breast cancer specimens were analyzed using Spearman, Kendall, and Pearson correlation tests. The Spearman and Kendall tests are rank correlations---the Spearman coefficient relates the two variables while conserving the order of data points, and the Kendall coefficient measures the number of ranks that match in the data set. We used the "cor" function in R statistical software for computation, specifying in the code which type of test we wanted (Spearman, Kendall, or Pearson). The significance of difference in mRNA expression level for each PHF among different subtypes and stages of breast cancer samples was calculated using ANOVA and Welch\'s *t*-test. To analyze the relationships between PHF mRNA expression and overall patient survival in breast cancer, samples were divided into higher and lower expression groups of each PHF, based on mRNA expression Z-scores \[RNA-Seq V2 RSEM (RNA-Seq by Expectation-Maximization)\] in TCGA dataset or the log~2~ normalized expression level in the METABRIC dataset. Multivariate survival analysis was conducted in TCGA breast cancer samples using the Cox regression function ("coxph") in R. Factors included in the multivariate analysis model were age at diagnosis (continuous variable), ER status (positive vs. negative), progesterone receptor status (positive vs. negative), HER2 status (positive vs. negative), tumor size (\>20 mm vs. ≤20 mm), lymph node status (positive vs. negative), metastasis status (positive vs. negative), and PAM50 subtype (basal vs. non-basal).
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